Steven Cohen Alnylam Pharmaceuticals, Inc. Transaction History
Point72 Asset Management, L.P.
- $40.1 Billion
- Q1 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 300,635 shares of ALNY stock, worth $129 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
300,635
Previous 300,635
-0.0%
Holding current value
$129 Million
Previous $81.2 Million
-0.0%
% of portfolio
0.2%
Previous 0.2%
Shares
18 transactions
Others Institutions Holding ALNY
# of Institutions
743Shares Held
110MCall Options Held
966KPut Options Held
866K-
Capital World Investors Los Angeles, CA16.7MShares$7.17 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$5.59 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.09 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$3.06 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.89 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $52.7B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...